Keywords: AstraZeneca, Brilinta, USA, FDA, Blood thinner, Antiplatelet, PLATO study

US FDA delays approval of AstraZeneca’s Brilinta, asking for more information

Article | 17 December 2010

Print This

Anglo-Swedish drug major AstraZeneca (LSE: AZN) received a setback yesterday, when the US Food and Drug Administration issued a complete ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in